Clinical Trial Search

Primary: Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score — -11.4; -7.5 units on a scale

Primary: Cognitive Function Measured by MCCB Composite Score — 35.39; 30.73 units on a scale

Primary: Number of Subjects With Serious Adverse Events (SAEs) — 71; 42; 37 Participants

Primary: Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens — 146; 156; 147; 147 Participants

Primary: Change From Baseline to Week 12 in 1h Post-dose FEV1 — 0.28; 0.24; 0.17 Liters — p=0.006

Primary: Mean Area Under the Curve (AUC) of Total Pain Reduction — 11.6; 11.7; 8.7 units on a scale*time scale — p=0.02

Primary: Any First Post-op Atrial Fibrillation or Flutter (AF) — 233; 227 Participants

Primary: Number of Subjects With Any Solicited Local Symptoms — 4; 2; 2; 0 Participants

Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants

Primary: 12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups — 35.4; 36.3 units on a scale — p=0.17

Primary: Anti-measles Virus Antibody Concentrations. — 1795.6; 1783.3 mIU/mL

Primary: For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG — 31620.9 ng•h/mL

Primary: Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score — 5.3; 5.47 BPI score — p=0.58

Primary: Percentage of Participants With Steady State Drug Concentration Ctrough (Cycle 6 Pre-dose) >20 µg/mL at Cycle 5. — 92.1; 93.3 Percentage of participants

Primary: PASI 75 Response Rate at Week 16 - GP2017 Adalimumab vs Humira ® Adalimumab — 66.8; 65.0 percent of participants